Aurobindo Pharma lifts margin, but other income remains material
Revenue grew 16.30% year on year and operating margin recovered 0.76 percentage points sequentially, though it remained below the healthcare peer median.
Filed 05 Aug 2026, 19:47 IST · after market close · Aurobindo Pharma Ltd (AUROPHARMA)
Key takeaways
- Consolidated net profit rose 25.22% year on year as revenue grew 16.30% and operating profit grew 17.34%.
- Operating margin improved 0.76 percentage points sequentially because expenses grew 2.38%, below the 3.35% increase in revenue.
- Other income contributed 14.69% of pre-tax profit, while the 31.88% tax rate limited the sequential increase in net profit to 12.07%.
Price around the results
Revenue growth translated into faster operating-profit growth
Aurobindo Pharma reported consolidated Q1FY27 revenue growth of 16.30% year on year, with operating profit growing faster at 17.34%; expenses increased 16.03%. Sequentially, revenue rose 3.35% and operating profit 7.32%, indicating better operating leverage than in Q4FY26. The results were filed after market close on 5 August 2026.
Margin recovered, but tax and other income affected profit quality
Operating margin expanded 0.19 percentage points year on year and 0.76 percentage points sequentially because costs grew more slowly than revenue in both comparisons. Other income accounted for 14.69% of pre-tax profit, making it a material contributor to reported earnings. The sequential tax-rate increase of 3.23 percentage points to 31.88% meant net profit grew 12.07%, below the 17.39% increase in pre-tax profit.
Margin is off the Q4FY26 low but below sector median
The 20.56% operating margin improved from 19.80% in Q4FY26, but remains below the 21.38% recorded in Q4FY25; the intervening trend was mixed rather than a continued decline. Among 42 healthcare peers that have reported the same quarter, the sector median operating margin was 22.54%, placing Aurobindo Pharma 1.98 percentage points below it and 18th from the bottom.
US launches and pipeline milestones remain key management disclosures
Management said the company received final approval for and launched 10 products in the US during Q1FY27. The company told investors that Omalizumab's EMA filing remains scheduled for Q3 2026, while Trastuzumab 600 mg SC is on track to enter clinical studies in 2026. Management also said TheraNym Unit 2 is planned as a greenfield drug-substance facility, with USD 180 million of estimated capex and qualification targeted for 2030, subject to clearances.
No immediate market reaction after the after-close filing
The stock had not yet reacted when the results were reported after market close. Across the last eight result reactions, the stock rose twice and fell six times, with a median absolute move of 1.02%; the recent pattern therefore leans negative, though the current response remains pending.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹9,150 cr | ₹8,853 cr | +3.35% | +16.30% |
| Other income | ₹223 cr | ₹115 cr | +94.15% | +107.53% |
| Expenses | ₹7,269 cr | ₹7,101 cr | +2.38% | +16.03% |
| Operating profit | ₹1,881 cr | ₹1,753 cr | +7.32% | +17.34% |
| Operating margin (%) | 20.56% | 19.80% | — | — |
| Interest | ₹102 cr | ₹98 cr | +3.51% | +4.00% |
| Depreciation | ₹487 cr | ₹479 cr | +1.72% | +20.00% |
| Profit before tax | ₹1,515 cr | ₹1,291 cr | +17.39% | +25.55% |
| Tax | ₹483 cr | ₹370 cr | +30.64% | +26.26% |
| Net profit | ₹1,032 cr | ₹921 cr | +12.07% | +25.22% |
| EPS (₹) | ₹17.86 | ₹15.86 | +12.61% | +25.77% |
Operating margin of 20.56% compares with a Healthcare sector median of 22.54% across 42 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company launched 10 products in the US during Q1FY27.
Guidance & outlook
- Omalizumab's EMA filing remains scheduled for Q3 2026.
- The merger of AuroVaccines into CuraTeQ is targeted for completion by March 2027.
- Trastuzumab 600 mg SC is on track to enter clinical studies in 2026.
- TheraNym Unit 2 is targeted to be ready for qualification in 2030.
Expansion
- TheraNym Unit 2 is a greenfield Drug Substance facility whose full-scale construction begins in October 2026, pending clearances.
- The company estimates USD 180 million of capex for TheraNym Unit 2.
New products
- The company received final approval for 10 products and launched 10 products in the US market.
- CuraTeQ's Trastuzumab 600 mg SC presentation will broaden its oncology franchise beyond IV formulations.
New initiatives
- TheraNym inaugurated Unit 1 on 3 June 2026 as part of its biologics contract manufacturing initiative.
Problems & risks
- TheraNym Unit 2 construction is subject to pending clearances.
What to watch
- Whether operating margin holds above 20.56% after the sequential recovery.
- Whether the tax rate moderates from 31.88% in the next quarter.
- Progress against management's reported Q3 2026 EMA filing schedule for Omalizumab.